Delineating the pathways driving cancer development and therapy resistance

Delineating the pathways driving cancer development and therapy resistance

Project details

Cancer is a complex disease caused by the aberrant expression of diverse gene products. Large sequencing studies have shed some light onto the nature of these cancer specific aberrations, but many of the critical tumour driving pathways and mutations that cause therapy resistance have not been discovered yet. To explore this, we have developed novel pre-clinical models, which will be combined with cutting edge CRISPR technology to unravel critical cancer driving and therapy resistance genes.

The PhD candidate will learn diverse CRISPR techniques (knockout, activation, base editing) to manipulate single genes and will use them as a screening tool in vitro and in vivo. These skills will be complemented with standard laboratory techniques (molecular cloning, western blotting, tissue culture, flow cytometry) and new nucleotide sequencing methods. Additionally, the candidate will have the possibility to acquire basic and advanced bioinfomatic analysis tools offered by the Institutes Bioinformatics division.

About our research group

Our lab is interested in blood cancers and finding new targets for cancer therapy. To this end we have developed diverse pre-clinical models and CRISPR screening platforms allowing the identification and validation of critical cancer driving genes (Janic A, Nature Medicine, 2018; Aubrey B, Cell Reports, 2015). New CRISPR editing tools, such as CRISPR activation or base editing, are currently being developed in our team as novel screening tools.

Our lab is based in the Blood Cells and Blood Cancer division and within this division we are closely collaborating with the Strasser and the Kelly groups. We are also collaborating with many additional groups across the Institute. This greatly enriches our work and allows us to tackle many exciting questions.

 

Email supervisors

 

Researchers:

Project Type: